Skip to Content
 
 
 
 

MCLA-128-CL01: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors

Objective

Clinical Trial Details >>

Principal Investigator(s)
Mark Huber, MD

Clinical Trial Categories

  • Genetics Studies
Contact
Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org

Location

  • Avera Cancer Institute at Sioux Falls
    1000 E. 23rd Street
    Sioux Falls, SD 57105
    Main: 605-322-3000
    Alternate: 800-657-4377

Moving Health Forward

Avera is a health ministry rooted in the Gospel. Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values.

© 2022 Avera Health, Sioux Falls, SD. All Rights Reserved.